ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Construction of an immunogenic cell death-based risk score prognosis model in breast cancer

Li, Yanling; Feng, Jianyuan; Wang, Ting; Li, Mingcui; Zhang, Hanyu; Rong, Zhiyuan; Cheng, Weilun; Duan, Yunqiang; Chen, Ziang; Hu, Anbang; Yu, Tianshui; Zhang, Jiarui; Shang, Yuhang; Zou, Yiyun; Ma, Fei*; Guo, Baoliang*哈尔滨医科大学
Frontiers in Genetics2022-12-13DOI: 10.3389/fgene.2022.1069921
4被引9阅读
引用收藏
分享

摘要

Immunogenic cell death (ICD) is a form of regulated cell death that elicits immune response. Common inducers of ICD include cancer chemotherapy and radiation therapy. A better understanding of ICD might contribute to modify the current regimens of anti-cancer therapy, especially immunotherapy. This study aimed to identify ICD-related prognostic gene signatures in breast cancer (BC). An ICD-based gene prognostic signature was developed using Lasso-cox regression and Kaplan-Meier survival analysis based on datasets acquired from the Cancer Genome Atlas and Gene Expression Omnibus. A nomogram model was developed to predict the prognosis of BC patients. Gene Set Enrichment Analysis (GESA) and Gene Set Variation Analysis (GSVA) were used to explore the differentially expressed signaling pathways in high and low-risk groups. CIBERSORT and ESTIMATE algorithms were performed to investigate the difference of immune status in tumor microenvironment of different risk groups. Six genes (CALR, CLEC9A, BAX, TLR4, CXCR3, and PIK3CA) were selected for construction and validation of the prognosis model of BC based on public data. GSEA and GSVA analysis found that immune-related gene sets were enriched in low-risk group. Moreover, immune cell infiltration analysis showed that the immune features of the high-risk group were characterized by higher infiltration of tumor-associated macrophages and a lower proportion of CD8(+) T cells, suggesting an immune evasive tumor microenvironment. We constructed and validated an ICD-based gene signature for predicting prognosis of breast cancer patients. Our model provides a tool with good discrimination and calibration abilities to predict the prognosis of BC, especially triple-negative breast cancer (TNBC).

学科与关键词

关键词
immunogenic cell deathimmunotherapybreast cancerprognosis modelRNA-seq
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2022-12-13
卷期
第 13 卷
页码
1069921
DOI
10.3389/fgene.2022.1069921
期刊等级
3区
成果收录
SCIE

作者

  • L

    Li, Yanling (第一作者)

    2 · harbin med univ

  • F

    Feng, Jianyuan

    2 · harbin med univ

查看全部 16 位作者收起作者
  • W

    Wang, Ting

    2 · harbin med univ

  • L

    Li, Mingcui

    2 · harbin med univ

  • Z

    Zhang, Hanyu

    2 · harbin med univ

  • R

    Rong, Zhiyuan

    2 · harbin med univ

  • C

    Cheng, Weilun

    2 · harbin med univ

  • D

    Duan, Yunqiang

    2 · harbin med univ

  • C

    Chen, Ziang

    2 · harbin med univ

  • H

    Hu, Anbang

    2 · harbin med univ

  • Y

    Yu, Tianshui

    2 · harbin med univ

  • Z

    Zhang, Jiarui

    2 · harbin med univ

  • S

    Shang, Yuhang

    2 · harbin med univ

  • Z

    Zou, Yiyun

    2 · harbin med univ

  • M

    Ma, Fei (通讯)

    2 · harbin med univ

  • G

    Guo, Baoliang (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417